Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
TIL ALERT: Ongoing Investigation Into Instil Bio, Inc. - Contact Levi & Korsinsky
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
Instil Bio shares slide on discontinuation of lead clinical programs
Instil Bio Pulls Plug On Lead Drug Development
Instil Bio shares slide on discontinuation of lead clinical programs
Instil Bio's Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco
Instil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Instil Bio Announces ImmuneOnco's Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC)
Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update
ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China
Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors
Instil Bio, Inc. (TIL) Is Up 4.07% in One Week: What You Should Know
Wall Street Analysts Think Instil Bio (TIL) Could Surge 246.68%: Read This Before Placing a Bet
Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program
Are You Looking for a Top Momentum Pick? Why Instil Bio, Inc. (TIL) is a Great Choice
Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer
Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference
Instil Bio (TIL) Upgraded to Buy: What Does It Mean for the Stock?
Wall Street Analysts Believe Instil Bio (TIL) Could Rally 343.63%: Here's is How to Trade
Instil Bio: Second-Half 2025 AXN-2510 Data Could Mark Another PD-1/VEGF Success
Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago
Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated in 2H 2025
Instil Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update
Instil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody
Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside
Instil Bio's Strategic Shift To SYN-2510: A Speculative 'Buy' Opportunity
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
2 Stocks Up Over 700% in 2024 That Could Soar Even Further
Crude Oil Surges Over 1%; Instil Bio Shares Plunge
Instil Bio Stock Skyrockets 641% in One Week: Here's Why
Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer
Up More Than 500% in 2024. Can Instil Bio Keep Rocketing Higher?
Instil Bio: PD-L1/VEGF Bispecific Targeting With Unique Enhancements
Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody
Q2 2024 Earnings Estimate for Precision BioSciences, Inc. (NASDAQ:DTIL) Issued By HC Wainwright
Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
What Makes Instil Bio (TIL) a New Buy Stock